Skip to main content

Artificial Cells for the Development of Cell Therapy

Buy Article:

$79.00 plus tax (Refund Policy)


In developing cell therapy, normal human cells are ideal as a cell source, but considering the serious lack of donor organs, it is unlikely to obtain a large enough amount of human cells. Moreover, even with current culturing techniques, the long-term culturing of normal human cells is difficult. On the other hand, in using xenogenic porcine cells and human tumor tissue-derived cell lines, there is concern that species-specific pathogens can be transmitted (such as infection by porcine endogenous retroviruses), and possible cancer may thus develop in recipients. Therefore, we are making efforts toward establishing reversible immortalized human cell lines that can be economically grown in tissue culture using the techniques of gene transfer in order to solve these problems. I here describe a strategy for establishing human reversibly immortalized cell lines that are intended for practical application in cell therapies. I would like to further contribute toward the realization of tissue engineering in fusional coordination with cell-processing technology by the utilization of such cell line constructing techniques.

Keywords: Cell therapies; Cre/loxP site-specific recombination; Hayflick's limit; Immortality; M1 phase; M2 phase; Reversible immortalization; Senescence

Document Type: Research Article


Affiliations: Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan

Publication date: 2008-01-01

More about this publication?
  • Cell Transplantation publishes original, peer-reviewed research and review articles on the subject of cell transplantation and its application to human diseases. To ensure high-quality contributions from all areas of transplantation, separate section editors and editorial boards have been established. Articles deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, among others. Basic clinical studies and immunological research papers are also featured. To provide complete coverage of this revolutionary field, Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell transplants. Cell Transplantation is now an Open Access journal starting with volume 18 in 2009, and therefore there will be an inexpensive publication charge, which is dependent on the number of pages, in addition to the charge for color figures. This will allow work to be disseminated to a wider audience and also entitle the corresponding author to a free PDF, as well as prepublication of an unedited version of the manuscript.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more